GMAB: Genmab A/S ADS Stocks News on November 4, 2025

GMAB

Insider Monkey

7 days ago

H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB)

How Recent Partnerships Are Shaping Genmab’s Value in 2025

GMAB

Simply Wall St.

8 days ago

How Recent Partnerships Are Shaping Genmab’s Value in 2025

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

GMAB

GlobeNewswire

14 days ago

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

GMAB

GlobeNewswire

21 days ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

GMAB

Simply Wall St.

22 days ago

Genmab (CPSE:GMAB) Valuation Insights Following Recent Share Price Climb

Is Genmab’s Rally Justified After Strong Quarterly Results in 2025?

GMAB

Simply Wall St.

23 days ago

Is Genmab’s Rally Justified After Strong Quarterly Results in 2025?

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.

GMAB

Barrons.com

25 days ago

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.

GMAB

Motley Fool

a month ago

Why Genmab Stock Popped on Friday

GMAB

Zacks

a month ago

What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now?

Why Genmab Stock Was Marching Higher Today

GMAB

Motley Fool

a month ago

Why Genmab Stock Was Marching Higher Today

Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium

GMAB

Insider Monkey

a month ago

Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium

GMAB

Insider Monkey

2 months ago

Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)

GMAB

Insider Monkey

2 months ago

Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S

GMAB

Simply Wall St.

2 months ago

Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed?

AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial

GMAB

Clinical Trials Arena

2 months ago

AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial

GMAB

MT Newswires

2 months ago

Genmab Says Outpatient Epcoritamab Treatment Feasible in Phase 2 Study

$Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)$

GMAB

Business Wire

2 months ago

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

GMAB

Insider Monkey

2 months ago

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

GMAB

Insider Monkey

2 months ago

Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

GMAB

Insider Monkey

2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

GMAB

Zacks

2 months ago

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

GMAB

GlobeNewswire

3 months ago

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

GlobeNewswire

3 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

Insider Monkey

3 months ago

William Blair Remains Bullish on Genmab A/S (GMAB)

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

GMAB

PR Newswire

3 months ago

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

GMAB

Zacks

3 months ago

Genmab (GMAB) Upgraded to Strong Buy: Here's Why

GMAB

Zacks

3 months ago

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

Transactions in Connection with Share Buy-back Program

GMAB

GlobeNewswire

4 months ago

Transactions in Connection with Share Buy-back Program

GMAB

GlobeNewswire

5 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GMAB

GlobeNewswire

5 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL

GMAB

Clinical Trials Arena

5 months ago

Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL

GMAB

MT Newswires

5 months ago

Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

$Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)$

GMAB

GlobeNewswire

5 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GMAB

GlobeNewswire

5 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data

GMAB

Pharmaceutical Technology

5 months ago

ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data

GMAB

Motley Fool

5 months ago

Why Genmab Stock Smashed It on Monday

GMAB

MT Newswires

5 months ago

Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

GMAB

GlobeNewswire

5 months ago

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

GMAB

Morningstar Research

5 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital

GMAB

TipRanks

5 months ago

Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital

GMAB

MT Newswires

5 months ago

RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

GMAB

GlobeNewswire

5 months ago

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

GMAB

Insider Monkey

5 months ago

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

GMAB

GlobeNewswire

5 months ago

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

GMAB

GlobeNewswire

5 months ago

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

GMAB

GlobeNewswire

5 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

GlobeNewswire

6 months ago

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

GMAB

GlobeNewswire

6 months ago

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

GMAB

GlobeNewswire

6 months ago

Transactions in Connection with Share Buy-back Program

GMAB

GuruFocus.com

6 months ago

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives

GMAB

MT Newswires

6 months ago

Genmab Q1 Earnings, Revenue Increase

Genmab Announces Financial Results for the First Quarter of 2024

GMAB

GlobeNewswire

6 months ago

Genmab Announces Financial Results for the First Quarter of 2024

GMAB

GlobeNewswire

6 months ago

Transactions in Connection with Share Buy-back Program

GMAB

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Premarket Friday

GMAB

MT Newswires

6 months ago

Genmab to Seek FDA Review of Follicular Lymphoma Combination Therapy

$Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)$